Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia

Srinivasa Subramaniam, Francesco Napolitano, Robert G. Mealer, Seyun Kim, Francesco Errico, Roxanne Barrow, Neelam Shahani, Richa Tyagi, Solomon H. Snyder, Alessandro Usiello

Research output: Contribution to journalArticlepeer-review

Abstract

L-DOPA-induced dyskinesia, the rate-limiting side effect in the therapy of Parkinson's disease, is mediated by activation of mammalian target of rapamycin (mTOR) signaling in the striatum. We found that Rhas -/- homolog enriched in striatum (Rhes), a striatal-specific protein, binds to and activates mTOR. Moreover, Rhes mice showed reduced striatal mTOR signaling and diminished dyskinesia, but maintained motor improvement on L-DOPA treatment, suggesting a therapeutic benefit for Rhes-binding drugs.

Original languageEnglish (US)
Pages (from-to)191-193
Number of pages3
JournalNature neuroscience
Volume15
Issue number2
DOIs
StatePublished - Feb 2012

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia'. Together they form a unique fingerprint.

Cite this